| Superior |
Inferior |
Parameterin comparison |
Reference |
| Basic Properties (in vitro) |
| AT- |
BM- |
MSC frequency |
[8,9] |
| AT- |
BM- |
metabolic activity |
[8] |
| AF- |
BM- |
proliferation |
[10] |
| WJ |
AT |
proliferation |
[23] |
| UC- |
PL- |
proliferation |
[21] |
| WJ- |
BM- |
proliferation |
[24] |
| PL- |
UC- |
adhesion capability |
[21] |
| AF- |
WJ- |
adhesion capability |
[22] |
| UC- |
PL- |
mass transport and cell migration |
[21] |
| Differentiation (in vitro) |
| BM- |
WJ- |
osteogenesis |
[24] |
| BM- |
AT- |
osteogenesis, chondrogenesis |
[13,26,27] |
| BM- |
PB- |
osteogenesis, adipogenesis |
[29] |
| BM-, AT- |
CB-, PL- |
adipogenesis |
[11,30] |
| PB- |
BM- |
chondrogenesis |
[29] |
| BM (fetal and adult) |
L (fetal), PL- |
chondrogeneisis |
[31] |
| AF- |
BM- |
hepatocyte differentiation |
[17] |
| I- |
BM- |
islet differentation |
[36] |
| UC-PSC |
BM- |
islet differentation |
[38] |
| BM- |
AT- |
islet differentation |
[37] |
| AF- |
BM- |
neural stem cell differentiation |
[39] |
| WJ- |
BM- or AT- |
neural progenitor cell differentiation |
[40] |
| AT- |
BM- |
neural stem cell differentiation |
[42] |
| UC- |
BM- |
endothelial differentiation |
[43] |
| AT- |
BM- |
sinus-like cell differentiation |
[44] |
| SM- |
AT-, or BM- |
myogenesis (rat) |
[45] |
| AT- |
BM- |
myogenesis (human) |
[46] |
| Immunomodulatory (in vitro) |
| AT- |
BM- |
suppressing -CD3/CD28 induced PBMC proliferation |
[8] |
| AT- |
BM- |
suppressing dendritic cell differentiation |
[48] |
| AT- |
BM- |
suppressing mitogen-stimulated Ig production |
[13] |
| H-, L- OE- |
BM- |
suppressing T cell activation |
[49] |
| OE- |
BM- |
suppressing NK cell activation |
[49] |
| OE-, L- (primed) |
BM- (primed) |
suppressing B cell activation |
[49] |
| CB, WJ-, BM- |
-- |
suppressing mitogen-stimulated PBMC proliferation |
[51] |
| PL- |
BM-, CB- |
suppressing a-CD3/CD28 induced T cell proliferation |
[52] |
| CP-, BM- |
-- |
suppressing T cell activation |
[53] |
| WJ- |
BM-, AT- |
suppressing mitogen-stimulated T cell proliferation |
[57] |
| CB- |
BM-, AT- |
anti-inflammatory effects |
[58] |
| AT- |
WJ-, BM- |
suppressing PHA-induced T cell activation |
[59] |
| AT-, WJ-, BM- |
-- |
suppressing NK cell activation |
[59] |
| Cell Therapy (in vivo) |
|
|
|
| AT- |
BM- |
regeneration following spinal cord injury (rat) |
[61] |
| AT-, BM-, WJ-, CB- |
-- |
early recovery from spinal cord injury (canine) |
[62] |
| AT- |
BM- |
improvement from stroke (mouse) |
[20] |
| CB- |
AT- |
inhibit GBM growth (mouse) |
[63] |
| AT- |
BM-, AM- |
wound closure (mouse) |
[66] |
| UC-, CB-, AT-, BM- |
-- |
osteogenesis following bone defect(rat) |
[67] |
| CB-, WJ-, AT-, BM- |
-- |
in vivoosteogenesis (canine) |
[68] |
| H- |
BM- |
cardiomyogenesis (rat) |
[25] |
| AT- |
BM-, SY- |
skeletal muscle regeneration (mouse) |
[72] |
| AT- |
BM- |
xeno-antibody production (rat) |
[80] |
